Sacubitril-valsartan for heart health in congenital heart disease
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests if a drug called sacubitril-valsartan can improve heart structure and function in adults with congenital heart disease. You will take the drug and have heart imaging to see changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with congenital heart disease (a heart condition you were born with).
- You are 18 years old or older.
- Your kidneys work well enough (creatinine clearance is above 30 ml/min).
- Your potassium level is not too high (below 5.2 mmol/l).
- Your blood pressure is not too low (at least 100 mmHg systolic).
- You are not pregnant, and you do not have a history of swelling from ACE inhibitors or ARBs.
- You are not currently taking certain medications (such as ACE inhibitors, ARBs, lithium, or others listed by the study).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called sacubitril/valsartan to see if it helps people who have both a prosthetic heart valve and heart failure with a weak heart pump. The goal is to improve heart function and symptoms.
This trial tests a medicine called sacubitril-valsartan for people in rural Tanzania with heart failure and reduced pumping strength. It aims to see if switching to this drug can improve symptoms and outcomes.
This study tests a medication that may help people with a specific type of heart disease (ATTR amyloidosis) and heart failure with reduced pumping function. The treatment could slow disease progression and improve symptoms.
This trial tests whether a combination of two blood pressure drugs (sacubitril/valsartan) is better than one drug alone (valsartan) at improving heart function in people with high blood pressure. It may help reduce strain on the heart's upper chambers.
This study tests whether a medication called sacubitril/valsartan can improve the heart's ability to relax and fill with blood (diastolic function) in people with heart failure with reduced ejection fraction. It may help improve your heart function and overall well-being.
This trial tests sacubitril/valsartan to help prevent heart weakness (cardiotoxicity) caused by breast cancer treatments like anthracyclines and/or anti-HER2 drugs. If you qualify, you may be offered this heart-protection medicine while your cancer is treated.
Hear when a new Congenital Heart Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.